Li Kang Biomedical Stock Fundamentals
| 6242 Stock | TWD 43.50 0.50 1.16% |
Li Kang Biomedical fundamentals help investors to digest information that contributes to Li Kang's financial success or failures. It also enables traders to predict the movement of 6242 Stock. The fundamental analysis module provides a way to measure Li Kang's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Li Kang stock.
6242 |
Li Kang Biomedical Company Current Valuation Analysis
Li Kang's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Li Kang Current Valuation | 1.05 B |
Most of Li Kang's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Li Kang Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Li Kang Biomedical has a Current Valuation of 1.05 B. This is 94.23% lower than that of the Personal Products sector and significantly higher than that of the Consumer Staples industry. The current valuation for all Taiwan stocks is 93.71% higher than that of the company.
Li Kang Biomedical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Li Kang's current stock value. Our valuation model uses many indicators to compare Li Kang value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Li Kang competition to find correlations between indicators driving Li Kang's intrinsic value. More Info.Li Kang Biomedical is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.62 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Li Kang Biomedical is roughly 1.60 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Li Kang's earnings, one of the primary drivers of an investment's value.6242 Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Li Kang's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Li Kang could also be used in its relative valuation, which is a method of valuing Li Kang by comparing valuation metrics of similar companies.Li Kang is currently under evaluation in current valuation category among its peers.
6242 Fundamentals
| Return On Equity | 0.19 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 1.05 B | |||
| Shares Outstanding | 23.31 M | |||
| Shares Owned By Insiders | 72.30 % | |||
| Price To Earning | 15.32 X | |||
| Price To Book | 2.30 X | |||
| Price To Sales | 1.94 X | |||
| Revenue | 386.97 M | |||
| Gross Profit | 264.68 M | |||
| EBITDA | 76.83 M | |||
| Net Income | 51.44 M | |||
| Cash And Equivalents | 187.44 M | |||
| Cash Per Share | 8.04 X | |||
| Total Debt | 24.59 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 2.56 X | |||
| Book Value Per Share | 23.12 X | |||
| Cash Flow From Operations | 60.45 M | |||
| Earnings Per Share | 4.16 X | |||
| Number Of Employees | 123 | |||
| Beta | 0.47 | |||
| Market Capitalization | 1.37 B | |||
| Total Asset | 616.07 M | |||
| Z Score | 33.0 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 616.07 M | |||
| Last Dividend Paid | 1.43 |
About Li Kang Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Li Kang Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Li Kang using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Li Kang Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drinks. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan. LI KANG operates under Travel Services classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 123 people.
Pair Trading with Li Kang
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Li Kang position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Li Kang will appreciate offsetting losses from the drop in the long position's value.Moving against 6242 Stock
The ability to find closely correlated positions to Li Kang could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Li Kang when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Li Kang - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Li Kang Biomedical to buy it.
The correlation of Li Kang is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Li Kang moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Li Kang Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Li Kang can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for 6242 Stock Analysis
When running Li Kang's price analysis, check to measure Li Kang's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Li Kang is operating at the current time. Most of Li Kang's value examination focuses on studying past and present price action to predict the probability of Li Kang's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Li Kang's price. Additionally, you may evaluate how the addition of Li Kang to your portfolios can decrease your overall portfolio volatility.